Decision: Favourable

Decisions Table

Study Title:

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies

  • NREC Code:

    22-NREC-CT-174

  • Decision:

    Favourable

  • Meeting Date:

    23/11/2022

  • Study Type:

    CT Application

  • Principal Investigator:

    Dr Patrick Thornton

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Merck Sharp & Dohme LLC

Scroll to Top